Thursday Feb 13, 2025

Dr Kamar Ameen-Ali - Addressing inequalities in access to dementia treatment

Dr Kamar Ameen-Ali narrates her blog written for Dementia Researcher.

In this blog Kamar discusses the inequalities in access to new Alzheimer's disease treatments following the UK approval of lecanemab and donanemab in 2024. Although these drugs were hailed as a breakthrough, they were not recommended for NHS use due to their high cost, limited efficacy, and safety concerns, meaning only those who can afford private treatment will benefit. This decision disproportionately affects lower socioeconomic groups, who are already at greater risk of developing dementia - not to mention others in low and middle income countries. With nearly a million people living with dementia in the UK, Kam stresses the need for a healthcare system capable of delivering future treatments equitably.

Find the original text, and narration here on our website.

https://www.dementiaresearcher.nihr.ac.uk/blog-addressing-inequalities-in-access-to-dementia-treatment/

Dr Kamar Ameen-Ali is a Lecturer in Biomedical Science at Teesside University & Affiliate Researcher at Glasgow University. In addition to teaching, Kamar is exploring how neuroinflammation following traumatic brain injury contributes to the progression of neurodegenerative diseases that lead to dementia. Having first pursued a career as an NHS Psychologist, Kamar went back to University in Durham to look at rodent behavioural tasks to completed her PhD, and then worked as a regional Programme Manager for NC3Rs.

Enjoy listening? We're always looking for new bloggers, drop us a line. http://www.dementiaresearcher.nihr.ac.uk

This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support.

Follow us on Social Media:

Comments (0)

To leave or reply to comments, please download free Podbean or

No Comments